NEW YORK – September 17, 2026 -- Inductive Bio has launched Indy, an AI medicinal chemistry agent that scored 89% accuracy on 84 real-program dose-response curves, versus 48% for Claude Opus 5 and 39% for GPT-5.6 Sol run at maximum effort settings.

Shanghai – September 17, 2026 -- MoleculeMind, an AI-native bioengineering infrastructure company, has had research on its reactive atomistic modeling platform QuantaMind published in Science Advances, demonstrating Density Functional Theory (DFT)-level accuracy in simulating 10,000-atom biomolecular systems over tens-of-nanosecond timescales.

Plymouth Meeting, Pa. – September 17, 2026 -- The National Comprehensive Cancer Network (NCCN) Oncology Research Program has awarded funding for four quality improvement projects targeting metastatic prostate cancer (mPCA) care, backed by Pfizer Global Medical Grants (GMG).

Seoul, South Korea – September 17, 2026 -- Yuyu Pharma has completed an 869-kilowatt (kW) solar installation at its Korean manufacturing facility, lifting total on-site solar capacity to approximately 1 megawatt (MW) and covering more than 30% of the plant's electricity needs.

San Rafael, Calif. – September 17, 2026 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has appointed Robert Plenge, M.D., Ph.D., to its Board of Directors, effective September 10, 2026.

Staten Island, N.Y. – September 17, 2026 -- Acurx Pharmaceuticals (NASDAQ: ACXP) presented new in vitro data showing its lead antibiotic ibezapolstat achieved a 5.51-log reduction against Clostridioides difficile in co-culture with vancomycin-resistant Enterococcus (VRE), significantly outperforming vancomycin (p=0.0112), the current standard of care.

The poster, presented by Dr. Eugenie Bassères of the University of Houston College of Pharmacy, was unveiled at the 9th International C. difficile Symposium in Bled, Slovenia, held September 8-10, 2026.

Los Angeles – September 17, 2026 -- The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to Armata Pharmaceuticals' AP-SA02, an intravenous multi-phage candidate for complicated Staphylococcus aureus bacteremia, stacking the designation atop existing Fast Track and Qualified Infectious Disease Product status.

Singapore – September 16, 2026 -- Researchers at the National University of Singapore (NUS) have eradicated tumours in 75 per cent of tested preclinical models using pulsed electromagnetic fields (PEMFs) alone, without chemotherapy, after just four 30-minute sessions. The study, led by Associate Professor Alfredo Franco-Obregón of the NUS Yong Loo Lin School of Medicine, was published in the journal Smart Medicine on June 4, 2026.

Chengdu – September 16, 2026 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) said phase III results for its HER2-targeted antibody-drug conjugate trastuzumab botidotin have been published in the Journal of Clinical Oncology, a journal with an impact factor of 44.7, after the drug outperformed Roche's trastuzumab emtansine (T-DM1) in a head-to-head trial and secured approval from China's National Medical Products Administration.

Gstaad – September 16, 2026 -- Tomonari Abe, President of 295-year-old Abe Yoando Pharma Co., Ltd., has become the first Japanese speaker in the history of the Longevity Investors Conference, running September 14-17, 2026 in Gstaad, Switzerland.